HanchorBio to Present Pipeline Strategy at 2026 Jefferies APAC Healthcare Conference
Management to discuss HCB101 as a clinical anchor, oncology platform expansion, and the emerging HCB206/HCB307 autoimmune franchise
TAIPEI, SHANGHAI, and SAN FRANCISCO — September 1, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that executive management will participate in the 2026 Jefferies APAC Healthcare Conference, taking place September 20–21, 2026, at Hilton Shanghai Zhangjiang Science Park in Shanghai.
Executive leadership will present the continued evolution of the Company’s proprietary FBDB™ platform, highlighting clinical progress of the lead candidate HCB101, pipeline expansion across multispecific HCB301 and HCB303 oncology assets, and the emerging HCB206 and HCB307 autoimmune franchise.
Key topics featured in the management presentation include:
- HCB101 — Clinical Anchor: Updated clinical activity for HanchorBio’s lead SIRPα-based macrophage-directed immunotherapy, including an 80% objective response rate (ORR) in the 5.12–8 mg/kg mid-dose cohorts of second-line gastric/gastroesophageal junction (GC/GEJ) cancer treated with ramucirumab and paclitaxel.
Additional clinical activity includes durable partial response beyond 80 weeks with HCB101 monotherapy in advanced HNSCC, a 50% ORR including a complete response in a Taiwan HNSCC study combining HCB101 with PD-1 blockade, and objective responses with prolonged disease control in colorectal cancer.
- Oncology Platform Expansion: Progress across trispecific programs HCB301 (SIRPα, PD-L1, TGFβ) and HCB303 (SIRPα, PD-L1, TIGIT/PVR), together with rational combination strategies incorporating complementary therapeutic modalities including targeted small molecules, vaccines, bispecific immunotherapies, and antibody-drug conjugates (ADCs).
- Autoimmune Franchise: Advancements of HCB206, designed for precision clearance of pathogenic CD20-positive B-cell compartments, and HCB307, designed for persistent immune-mediated disease involving pathogenic immune-cell compartments beyond conventional CD20-positive B cells. HCB307 is advancing toward IND submission. The two programs target distinct disease biology and patient populations rather than representing sequential generations of the same therapeutic strategy.
Meet with HanchorBio at Jefferies APAC
Institutional investors, corporate partners, and other healthcare industry participants wishing to schedule a 1-on-1 meeting with HanchorBio may submit a request through the Jefferies APAC Healthcare Conference meeting portal or contact the Company directly at [email protected].
The inaugural Jefferies APAC Healthcare Conference is expected to convene more than 80 leading healthcare companies and facilitate more than 700 meetings, including one-on-one and small-group discussions between institutional investors and senior corporate management.
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company focused on inventing next-generation biologics for cancer and immune-mediated diseases using its proprietary FBDB™ platform.
HanchorBio’s pipeline includes HCB101, its lead SIRPα-based innate immune checkpoint program; HCB301, a clinical-stage trispecific immunotherapy targeting SIRPα, PD-L1, and TGF-β biology; HCB303, a next-generation trispecific program integrating SIRPα, PD-L1, and TIGIT/PVR biology; and additional programs across oncology and immune-mediated diseases.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the clinical development and potential of HCB101, HCB301, HCB303, HCB206, HCB307 and other product candidates; the timing and potential submission of regulatory applications, including an IND for HCB307; future development strategies; potential therapeutic characteristics of HanchorBio’s product candidates; and the capabilities and potential of the FBDB™ platform.
These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. Development timelines, regulatory plans, clinical strategies and potential therapeutic applications may change as additional data become available and regulatory interactions occur. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
漢康生技將於 2026 Jefferies亞太醫療健康大會分享產品線策略
管理團隊將聚焦 HCB101 臨床核心定位、腫瘤平台拓展，以及 HCB206／HCB307 自體免疫產品布局
【台北、上海、舊金山，2026 年 9 月 1 日】－全球臨床階段生技公司漢康生技（TWSE：7827），致力於開發應用於腫瘤及免疫介導疾病的次世代免疫療法，今日宣布，公司高階管理團隊將參加於 2026 年 9 月 20 至 21 日在上海張江科學園區希爾頓酒店舉行的 2026 Jefferies亞太醫療健康大會 (APAC Healthcare Conference)。
公司高階管理團隊將於會中分享自有 FBDB™ 平台的持續發展，重點包括核心候選藥物 HCB101 的臨床進展、多特異性腫瘤產品 HCB301 與 HCB303 的產品線拓展，以及逐步成形的 HCB206 與 HCB307 自體免疫產品布局。
管理團隊簡報將聚焦以下重點：
- HCB101－臨床核心： 更新漢康生技核心 SIRPα 巨噬細胞導向免疫療法 HCB101 的臨床進展。在第二線胃癌／胃食道交界處癌（GC/GEJ）中，HCB101 與 ramucirumab 及 paclitaxel 聯合治療，在 5.12–8 mg/kg 中劑量組觀察到 80% 客觀緩解率（ORR）。
其他臨床觀察包括，HCB101 單藥治療晚期頭頸部鱗狀細胞癌（HNSCC）患者出現持續超過 80 週的部分緩解（PR）；在台灣進行的頭頸癌研究中，HCB101 聯合 PD-1 抑制劑治療觀察到 50% ORR，其中包括一例完全緩解（CR）；此外，在大腸直腸癌患者中亦觀察到客觀緩解及較長期的疾病控制（SD）。
- 腫瘤平台拓展： 推進三特異性產品 HCB301（SIRPα、PD-L1、TGFβ）與 HCB303（SIRPα、PD-L1、TIGIT/PVR），並同步評估與具互補作用機制的治療方式進行合理聯合，包括標靶小分子藥物、疫苗、雙特異性免疫療法及抗體藥物複合體（ADC）。
- 自體免疫產品布局： 推進 HCB206 與 HCB307。HCB206 旨在精準清除致病性 CD20 陽性 B 細胞族群；HCB307 則針對涉及傳統 CD20 陽性 B 細胞以外致病性免疫細胞族群的持續性免疫介導疾病進行設計，目前正朝向提交新藥臨床試驗申請（IND）推進。兩項產品分別針對不同疾病生物學機制與患者族群，並非同一治療策略的前後世代產品。
與漢康生技於 Jefferies APAC 會面
有意與漢康生技安排一對一會議的機構投資人、企業合作夥伴及其他醫療產業人士，可透過 Jefferies亞太醫療健康大會會議平台提出申請，或直接聯繫漢康生技：[email protected]。
首屆 Jefferies亞太醫療健康大會預計將匯聚超過 80 家領先醫療健康企業，並促成超過 700 場會議，包括機構投資人與企業高階管理團隊之間的一對一及小型團體交流。
關於漢康生技
漢康生技（TWSE：7827）是一家全球臨床階段生技公司，透過自有 FBDB™ 平台，專注於開發應用於癌症及免疫介導疾病的次世代生物藥。
漢康生技目前產品線包括：以 SIRPα 為基礎的先天免疫檢查點核心候選藥物 HCB101；針對 SIRPα、PD-L1 與 TGF-β 生物學機制、已進入臨床階段的三特異性免疫療法 HCB301；整合 SIRPα、PD-L1 與 TIGIT/PVR 生物學機制的次世代三特異性產品 HCB303；以及其他布局於腫瘤與免疫介導疾病領域的研發項目。
前瞻性聲明
本新聞稿包含前瞻性聲明，包括有關 HCB101、HCB301、HCB303、HCB206、HCB307 及其他候選產品之臨床開發及潛力；法規申請的預計時程及可能提交情形，包括 HCB307 的 IND 申請；未來開發策略；漢康生技候選產品可能具備之治療特性；以及 FBDB™ 平台的能力與潛力等相關陳述。
上述聲明係基於目前的預期及假設，並涉及可能導致實際結果與本篇所述內容產生重大差異的風險及不確定性。隨著更多數據取得及與主管機關進一步互動，產品開發時程、法規計畫、臨床策略及潛在治療應用均可能有所調整。除適用法律另有規定外，漢康生技無義務更新任何前瞻性聲明。